Previous 10 | Next 10 |
Abstracts Include Three Post-hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world Evidence Further Establishes Relationship Between Higher Levels of Hemoglobin and Decreas...
Portola Pharmaceuticals (NASDAQ: PTLA) might be relatively unheard of compared to its more popular peers. However, the $2.1 billion biotech stock has some promising drug candidates in the pipeline, with at least one poised to become a major blockbuster. Over the past couple of years, Porto...
Fundamentals Global Blood Therapeutics ( GBT ) most recent 10-Q Capital structure The company is well-funded and should be sufficient to fund the initial marketization up until the full approval of Voxelotor. I theorize that this would be the best time to capitalize in the form ...
First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13 th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (...
Shares of Global Blood Therapeutics (GBT) have more than doubled since my 2016 article outlined an attractive opportunity in the sickle cell disease space and touched on promising early stage data for voxelotor (known as GBT440 back then). However, performance has been essentially flat since...
Drug development is hard and expensive, but so is commercialization. Biotechs that persevere and make it through late-stage pivotal trials face the challenges of gaining regulatory approval. Many biotech companies will never endure this because promising drug candidates often get licensed by m...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stoc...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD) research have been accepted for oral and poster presentations during the 47 th Annual National Sic...
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy fo...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...